Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man

This publication has 14 references indexed in Scilit:

• Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma
  Cancer Immunology, Immunotherapy, 1999
• Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen
  Cancer Immunology, Immunotherapy, 1998
• 722: Randomized phase III trial of active specific immunotherapy (ASI) versus control in patients with Duke's B2, B3 or C colon cancer
  European Journal Of Cancer, 1997
• Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.
  Proceedings of the National Academy of Sciences, 1996
• Evaluation of tolerability and antibody response after recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and a single dose of recombinant hepatitis B vaccine
  Vaccine, 1996
• Vaccination of rhesus monkeys with an anti-idiotype antibody mumicking Lewis Y: Enhancement of the anti-tumor immune response by repeated administrations of recombinant human GM-CSF.
  European Journal Of Cancer, 1995
• Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: Comparison of adenovirus- and retrovirus-mediated genetic transduction
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1995
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
  Proceedings of the National Academy of Sciences, 1993
• Active specific immunotherapy with Newcastle-diseasevirus-modified autologous tumor cells following resection of liver metastases in colorectal cancer
  Cancer Immunology, Immunotherapy, 1992
• Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine
  JNCI Journal of the National Cancer Institute, 1992